<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="34164">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02661841</url>
  </required_header>
  <id_info>
    <org_study_id>0086-15 HYMC</org_study_id>
    <nct_id>NCT02661841</nct_id>
  </id_info>
  <brief_title>Effectiveness of Lung Impedance Guided Preemptive Therapy of Chronic Heart Failure Patients With Preserved Ejection Fraction (LVEF ≥ 45%) in Our Hospital's Outpatient Clinic</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hillel Yaffe Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hillel Yaffe Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      We aim to determine the effectiveness of lung impedance guided preemptive therapy
      (LI-Guided) of chronic heart failure patients with preserved ejection fraction (LVEF ≥ 45%)
      who are being treated in our hospital's outpatient clinic.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>February 2016</start_date>
  <completion_date type="Anticipated">January 2021</completion_date>
  <primary_completion_date type="Anticipated">January 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single Blind (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Reduced all cause, cardiovascular, and heart failure hospitalizations</measure>
    <time_frame>Five years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Reduced mortality</measure>
    <time_frame>Five years</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Heart Failure</condition>
  <arm_group>
    <arm_group_label>LI-Guided Therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>One hundred and fifty chronic heart failure patients treated based on guidelines and LI-Guided Therapy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>One hundred and fifty chronic heart failure patients treated based on guidelines only.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>LI-Guided Therapy</intervention_name>
    <description>Preemptive treatment according to LI monitoring</description>
    <arm_group_label>LI-Guided Therapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Heart Failure Guidelines</intervention_name>
    <description>Treatment according to clinical signs</description>
    <arm_group_label>LI-Guided Therapy</arm_group_label>
    <arm_group_label>Control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients hospitalized within past 12 months for heart failure

        Exclusion Criteria:

          -  Dialysis patients

          -  Patients with GFR &lt;25

          -  Patients with serious illness and life expectancy &lt;12

          -  Mentally incompetent
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael Shochat, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hillel Yaffe Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Michael Shochat, MD, PhD</last_name>
    <phone>972-4-630-4491</phone>
    <email>shochat1@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hillel Yaffe Medical Center</name>
      <address>
        <city>Hadera</city>
        <zip>38100</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael Shochat, MD, PhD</last_name>
      <phone>972-4-630-4491</phone>
      <email>shochat@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <verification_date>June 2016</verification_date>
  <lastchanged_date>June 1, 2016</lastchanged_date>
  <firstreceived_date>January 20, 2016</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
